Enrollment and Randomization of 12463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial - BioSpace

Enrollment and Randomization of 12463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial  BioSpace

Comments

Popular posts from this blog